Countdown to Teleflex (TFX) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS
Analysts on Wall Street project that Teleflex (TFX) will announce quarterly earnings of $3.26 per share in its forthcoming report, representing a decline of 7.4% year over year. Revenues are projected to reach $768.47 million, increasing 1.4% from the same quarter last year.
The consensus EPS estimate for the quarter has undergone a downward revision of 0.1% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
In light of this perspective, let's dive into the average estimates of certain Teleflex metrics that are commonly tracked and forecasted by Wall Street analysts.
Analysts expect 'Net Revenues- Interventional' to come in at $132.46 million. The estimate indicates a change of +5.9% from the prior-year quarter.
The average prediction of analysts places 'Net Revenues- Interventional Urology' at $90.70 million. The estimate suggests a change of +1.7% year over year.
Analysts forecast 'Net Revenues- OEM' to reach $76.49 million. The estimate suggests a change of +3.8% year over year.
Based on the collective assessment of analysts, 'Net Revenues- Vascular Access' should arrive at $185.21 million. The estimate indicates a year-over-year change of -0.6%.
Analysts predict that the 'Net Revenues- Anesthesia' will reach $100.10 million. The estimate points to a change of +0.5% from the year-ago quarter.
According to the collective judgment of analysts, 'Net Revenues- Other' should come in at $68.08 million. The estimate indicates a change of -7.5% from the prior-year quarter.
The collective assessment of analysts points to an estimated 'Net Revenues- Surgical' of $112.62 million. The estimate points to a change of +2% from the year-ago quarter.
The consensus among analysts is that 'Geographic Revenues- Americas' will reach $455.49 million. The estimate indicates a year-over-year change of -0.6%.
The combined assessment of analysts suggests that 'Geographic Revenues- Asia' will likely reach $83.62 million. The estimate indicates a change of +6.5% from the prior-year quarter.
It is projected by analysts that the 'Geographic Revenues- EMEA' will reach $158.19 million. The estimate points to a change of +7% from the year-ago quarter.
View all Key Company Metrics for Teleflex here>>>
Shares of Teleflex have experienced a change of +1.7% in the past month compared to the +5.2% move of the Zacks S&P 500 composite. With a Zacks Rank #4 (Sell), TFX is expected to underperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Teleflex Incorporated (TFX) : Free Stock Analysis Report
